KERX Profile
Keryx
Biopharmaceuticals, Inc. (KERX) is a biopharmaceutical company that
focuses on the development of therapies for patients with renal
diseases. The company’s lead product, Auryxia (ferric citrate), is an
oral, iron-based compound that acts as a phosphate binder and is used
for the treatment of hyperphosphatemia in patients with chronic kidney
disease (CKD) who are on dialysis.
Auryxia was approved by the
FDA in September 2014, and it is the first and only phosphate binder
that has been approved for the treatment of hyperphosphatemia in
patients with CKD who are on dialysis. The drug works by binding to
phosphate in the GI tract, which reduces the amount of phosphate that
is absorbed into the bloodstream. Auryxia has been shown to be
effective in lowering serum phosphorus levels, and it has also been
shown to be well-tolerated in clinical trials.
In addition to
Auryxia, Keryx is also developing a drug called Zerenex (ferric
citrate coordination complex), which is an iron-based compound that
acts as a phosphate binder and an iron replacement therapy. Zerenex
has been shown to be effective in reducing serum phosphorus levels and
increasing hemoglobin levels in clinical trials, and it is currently
in Phase III clinical trials for the treatment of hyperphosphatemia in
patients with CKD who are not on dialysis.
Keryx is also
exploring other potential indications for Auryxia and Zerenex,
including the treatment of iron deficiency anemia in patients with CKD
and the treatment of hyperphosphatemia in patients with stage 3 or 4
CKD.
Overall, Keryx is a biopharmaceutical company that is
focused on the development of therapies for patients with renal
diseases, and it has made significant progress in this area with the
approval of Auryxia and the development of Zerenex. The company’s
pipeline of potential therapies and indications for its existing
products provides a strong foundation for future growth a
|
